LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

BioCryst Pharmaceuticals Inc

Fechado

SetorSaúde

8.28 -0.24

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.27

Máximo

8.46

Indicadores-chave

By Trading Economics

Rendimento

5.1M

5.1M

Vendas

18M

163M

Margem de lucro

3.113

Funcionários

580

EBITDA

-84M

-62M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+110.59% upside

Dividendos

By Dow Jones

Próximos Ganhos

3 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-88M

1.7B

Abertura anterior

8.52

Fecho anterior

8.28

Sentimento de Notícias

By Acuity

32%

68%

94 / 371 Ranking em Healthcare

BioCryst Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de set. de 2025, 23:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

2 de set. de 2025, 22:10 UTC

Grandes Movimentos do Mercado

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

2 de set. de 2025, 21:47 UTC

Ganhos

Alimentation Couche-Tard Logs Lower Profit, Revenue in 1Q

2 de set. de 2025, 16:52 UTC

Grandes Movimentos do Mercado

CleanCore Solutions Shares Drop After $175 Million Private Investment

2 de set. de 2025, 22:47 UTC

Conversa de Mercado

Google, Apple Can Grow AI Deal With Lawsuit Resolved -- Market Talk

2 de set. de 2025, 21:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Investors Have to Be Ready for State Capitalism. What Areas to Watch. -- Barrons.com

2 de set. de 2025, 21:07 UTC

Ganhos

Couche-Tard 1Q U.S. Same-Store Merchandise Revenue Up 0.4% >ATD.T

2 de set. de 2025, 21:07 UTC

Ganhos

Couche-Tard 1Q Canada Same-Store Merchandise Revenue Up 4.1% >ATD.T

2 de set. de 2025, 21:05 UTC

Ganhos

Couche-Tard 1Q Rev $17.35B >ATD.T

2 de set. de 2025, 21:05 UTC

Ganhos

Couche-Tard 1Q Adj EPS 78c >ATD.T

2 de set. de 2025, 21:05 UTC

Ganhos

Couche-Tard 1Q EPS 82c >ATD.T

2 de set. de 2025, 21:05 UTC

Ganhos

Couche-Tard 1Q Net $782.5M >ATD.T

2 de set. de 2025, 21:00 UTC

Conversa de Mercado

ESG Roundup: Market Talk

2 de set. de 2025, 20:53 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Knight-Swift Transportation Endorses Union Pacific, Norfolk Southern Merger -- Market Talk

2 de set. de 2025, 20:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Buffett Dislikes Breakup of Kraft Heinz. It's Been One of His Worst Investments. -- Barrons.com

2 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

2 de set. de 2025, 20:27 UTC

Ganhos

NIO Stock Rises After Second-Quarter Loss Narrows -- Barrons.com

2 de set. de 2025, 20:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

2 de set. de 2025, 20:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Procter & Gamble Does Not Endorse Tutanota's Unsolicited Mini-Tender Offer >PG

2 de set. de 2025, 20:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Procter & Gamble: Tutanota Says It Expects to Extend Offer for Successive Periods of Up to 180 Days Until Market Price Exceeds Offer Price >PG

2 de set. de 2025, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Procter & Gamble: 'Shareholders Who Tender Their Shrs in the Offer Will Receive a Below-Market Price' >PG

2 de set. de 2025, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Procter & Gamble: Offer by Tutanota Is to Purchase Up to 500,000 Shrs at $128 Each

2 de set. de 2025, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Procter & Gamble Has Been Notified of Unsolicited Mini-Tender Offer by Tutanota >PG

2 de set. de 2025, 19:55 UTC

Ganhos

GM Had a Record Month of EV Sales. A 'Collapse' Is Coming. -- Barrons.com

2 de set. de 2025, 19:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Food Giants Are Struggling. Could Mergers, Spinoffs, and Activist Stakes Help? -- Barrons.com

2 de set. de 2025, 19:09 UTC

Conversa de Mercado

Oil Futures Gain on Geopolitical Premium -- Market Talk

2 de set. de 2025, 19:00 UTC

Conversa de Mercado

U.S. Natural Gas Futures Recover $3 Level -- Market Talk

2 de set. de 2025, 18:12 UTC

Conversa de Mercado

Gold Pushes To New Record -- Market Talk

2 de set. de 2025, 17:04 UTC

Conversa de Mercado

Philip Morris Riding Smoke-Free Products to Higher Margins -- Market Talk

2 de set. de 2025, 16:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

Comparação entre Pares

Variação de preço

BioCryst Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

110.59% parte superior

Previsão para 12 meses

Média 17.5 USD  110.59%

Máximo 30 USD

Mínimo 12 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para BioCryst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

94 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.